320 related articles for article (PubMed ID: 20530422)
1. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
2. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
[TBL] [Abstract][Full Text] [Related]
5. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
8. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
[TBL] [Abstract][Full Text] [Related]
9. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
10. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
Wang X; Wang G; Dong D; Fu S; Yang B
Exp Toxicol Pathol; 2008 Sep; 60(6):481-8. PubMed ID: 18606528
[TBL] [Abstract][Full Text] [Related]
11. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
12. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
Longley DB; Boyer J; Allen WL; Latif T; Ferguson PR; Maxwell PJ; McDermott U; Lynch M; Harkin DP; Johnston PG
Cancer Res; 2002 May; 62(9):2644-9. PubMed ID: 11980662
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of survivin mRNA.
Cheng B; Yang X; Han Z; An L; Liu S
Auris Nasus Larynx; 2008 Mar; 35(1):95-101. PubMed ID: 17869043
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
15. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
16. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
17. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
Dolnick R; Wu Q; Angelino NJ; Stephanie LV; Chow KC; Sufrin JR; Dolnick BJ
Cancer Res; 2005 Jul; 65(13):5917-24. PubMed ID: 15994970
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
20. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
